Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like OptionsSeeking Alpha · Oct 6, 2026
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual MeetingGlobeNewsWire · Sep 29, 2026
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial AnalysisDefense World · Sep 21, 2026
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareGlobeNewsWire · Sep 4, 2026
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon CorpDefense World · Sep 4, 2026
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt DiseaseGlobeNewsWire · Sep 3, 2026Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.19 | -$0.43 | Miss |
| May 6, 2026 | -$0.40 | -$0.16 | Beat |
| Feb 23, 2026 | -$0.10 | -$0.20 | Miss |
| Nov 4, 2025 | -$0.35 | -$0.30 | Beat |
| Aug 6, 2025 | -$0.33 | -$0.48 | Miss |
| May 1, 2025 | -$0.69 | -$0.64 | Beat |